Insider Transactions in Q2 2024 at Iovance Biotherapeutics, Inc. (IOVA)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,784
-4.29%
|
$14,272
$8.37 P/Share
|
|
Jun 03
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,516
+7.8%
|
-
|
|
Jun 03
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,982
-4.27%
|
$15,856
$8.37 P/Share
|
|
Jun 03
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+7.75%
|
-
|
|
Jun 03
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,426
-2.92%
|
$35,408
$8.37 P/Share
|
|
Jun 03
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+6.42%
|
-
|
|
Apr 15
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,427
-3.62%
|
$15,697
$11.89 P/Share
|
|
Apr 15
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+6.65%
|
-
|
|
Apr 15
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,427
-3.24%
|
$15,697
$11.89 P/Share
|
|
Apr 15
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+6.01%
|
-
|
|
Apr 15
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-5.89%
|
$97,361
$11.89 P/Share
|
|
Apr 15
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+12.18%
|
-
|